© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Jeffrey Aldrich, MD, is currently a second-year fellow at Emory University School of Medicine. He went to medical school at Sidney Kimmel Medical College at Thomas Jefferson University and had his residency at Baylor College of Medicine.
June 01, 2022
Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.